P.3.c.001 A randomized double blind clinical trial in famotidine adjuvant therapy in schizophrenia

Pharmacological Management of Persistent Hostility and Aggression in Persons With Schizophrenia Spectrum Disorders: A Systematic Review

“…63 Other measures that are perhaps similar were reportedly employed, but neither described nor identified by citation, such as the PANSS "supplemental anger item," 70 the PANSS "aggression supplemental scale," 71 and the "aggressiveness risk" score (perhaps referring to the Aggression Risk Profile). 72 The measures employed were sometimes reported ambiguously, in which case the scale that seemed to most likely have been used in a study was decided by consensus. Other identifiable measures employed included the Buss-Durkee Hostility Inventory, 73 the Plutchik Impulsivity scale, 74 84 ), the anger item on the State-Trait Personality Inventory, 85 seclusion and restraint data, or ad hoc rudimentary measures such as occurrence or nonoccurrence of any known aggressive behavior during an arbitrarily selected time period (e.g., 57,86,87 ) or a "rough evaluation" of aggressiveness.…”

“…Does evidence exist that any adjunctive medication will reduce overt aggression or hostility in persons with schizophrenia spectrum disorders? [70][71][72]88,[132][133][134][135][136][137][138][139][140][141][142] (Table 4) Fifteen articles were identified that reported relevant data. One paper 137 was also reported in Table 5 because the subjects were preselected for aggressiveness.…”

Famotidine Augmentation in Schizophrenia: Hope or Hype?

“…Farzin et al 15 recruited 30 schizophrenia patients who had not responded to at least 2 previous antipsychotic trials. These patients were randomized to receive famotidine (60 mg/d) or placebo for 6 weeks.…”

“…3. Three RCTs on famotidine augmentation in refractory schizophrenia 2,13,15 reported benefits on different outcome measures and to different extents (10%-27% superiority over placebo). 4.…”

“…Of the remaining 3 RCTs, 2,13,15 all with results favoring famotidine augmentation in antipsychotic-refractory schizophrenia, 1 13 could not be evaluated because the full text was not in English. One found that famotidine outperformed placebo by a large margin (27%), 15 and 1 found that famotidine outperformed placebo by only a small margin (10%), 2 which falls well below the threshold of most definitions of treatment response even in refractory schizophrenia. Only 1 RCT 2 presented a sound statistical plan, and no RCT corrected for type I errors arising from multiple testing.…”